Artiva Biotherapeutics, Inc.
ARTV
$2.88
$0.113.97%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | 0.00 | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | 0.00 | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | 0.00 | -- | -- |
SG&A Expenses | 4.95M | 5.12M | 4.95M | 4.81M | 3.86M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 22.81M | 22.17M | 18.27M | 18.34M | 16.19M |
Operating Income | -22.81M | -22.17M | -18.27M | -18.34M | -16.19M |
Income Before Tax | -21.25M | -20.31M | -16.10M | -17.47M | -17.84M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -21.25M | -20.31M | -16.10M | -17.47M | -17.84M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -21.25M | -20.31M | -16.10M | -17.47M | -17.84M |
EBIT | -22.81M | -22.17M | -18.27M | -18.34M | -16.19M |
EBITDA | -22.17M | -21.54M | -17.65M | -17.71M | -15.59M |
EPS Basic | -0.87 | -0.83 | -0.66 | -0.92 | -22.00 |
Normalized Basic EPS | -0.54 | -0.52 | -0.89 | -0.58 | -13.75 |
EPS Diluted | -0.87 | -0.83 | -1.32 | -0.92 | -22.00 |
Normalized Diluted EPS | -0.54 | -0.52 | -0.89 | -0.58 | -13.75 |
Average Basic Shares Outstanding | 24.38M | 24.34M | 24.39M | 18.90M | 811.20K |
Average Diluted Shares Outstanding | 24.38M | 24.34M | 24.39M | 18.90M | 811.20K |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |